SGHT (Sight Sciences) 3-Month Share Buyback Ratio: -1.26% (As of Jun. 2026 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SGHT Sight Sciences Inc SGHT
70 GF Score
Price $7.48
GF Value $4.57
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Sight Sciences 3-Month Share Buyback Ratio?

Sight Sciences SGHT +5.36% 70 3-Month Share Buyback Ratio is -1.26 as of Jun. 2026. GuruFocus rates SGHT with a GF Score™ of 70/100 and a GF Value™ of $4.57 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Sight Sciences's current 3-Month Share Buyback Ratio was -1.26%.


Sight Sciences  (NAS:SGHT) 3-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.


Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.


Sight Sciences 3-Month Share Buyback Ratio Related Terms


SGHT vs TMCI, TLSI, SENS: 3-Month Share Buyback Ratio Comparison

For the Medical Devices subindustry, Sight Sciences's 3-Month Share Buyback Ratio, along with its competitors' market caps and 3-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sight Sciences 3-Month Share Buyback Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sight Sciences's 3-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Sight Sciences's 3-Month Share Buyback Ratio falls into.


SGHT
70GF Score
Sight Sciences Inc SGHT
3-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sight Sciences 3-Month Share Buyback Ratio Calculation

Sight Sciences's 3-Month Share Buyback Ratio for the quarter that ended in Jun. 2026 is calculated as

3-Month Share Buyback Ratio=(Shares Outstanding (EOP) (Mar. 2026 ) - Shares Outstanding (EOP) (Jun. 2026 )) / Shares Outstanding (EOP) (Mar. 2026 )
=(54.034 - 54.506) / 54.034
=-0.87%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a 3-Month Share Buyback Ratio of -1.26 mean?
Sight Sciences (SGHT) has a 3-Month Share Buyback Ratio of -1.26 as of Jun. 2026. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Sight Sciences and its competitors.
Is Sight Sciences' 3-Month Share Buyback Ratio too high?
Sight Sciences' current 3-Month Share Buyback Ratio is -1.26. Overall, Sight Sciences has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sight Sciences' 3-Month Share Buyback Ratio compare to TMCI and TLSI?
Sight Sciences' 3-Month Share Buyback Ratio of -1.26 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Month Share Buyback Ratio for a Medical Devices & Instruments company?
A good 3-Month Share Buyback Ratio depends on the Medical Devices & Instruments industry context. However, 3-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Month Share Buyback Ratio mean?
A high 3-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Sight Sciences and its competitors. Sight Sciences's current 3-Month Share Buyback Ratio is -1.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sight Sciences stock overvalued right now?
Based on GuruFocus' analysis, Sight Sciences (SGHT) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.57, compared to a current price of $7.48 — trading 63.7% above its estimated fair value. The current 3-Month Share Buyback Ratio is -1.26. Sight Sciences' overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Month Share Buyback Ratio calculated?
3-Month Share Buyback Ratio is calculated from a company's financial statements. For Sight Sciences (SGHT), the current 3-Month Share Buyback Ratio is -1.26 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sight Sciences (SGHT) Overvalued in 2026?

Based on GuruFocus' analysis, Sight Sciences stock appears to be overvalued. The current stock price of $7.48 is trading 63.7% above its estimated GF Value™ of $4.57. GuruFocus considers Sight Sciences to be Significantly Overvalued.

Key valuation signals for SGHT:

  • 3-Month Share Buyback Ratio: -1.26
  • GF Value™: $4.57 vs. price of $7.48 (63.7% above fair value)
  • GF Score™: 70/100 with 3 warning signs

No single metric tells the full story. See the SGHT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sight Sciences Business Description

Address 4040 Campbell Avenue, Suite 100, Menlo Park, CA, USA, 94025
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
70GF Score

Get the complete analysis for SGHT

3-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.48
Price
$4.57
GF Value